PALO ALTO, Calif. (October 15, 2024) — FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings at the 2024 Veterinary Cancer Society (VCS) Annual Conference. This research, Genetic Alterations Associated with Prognosis and Better Therapeutic Outcomes in Dogs with
Splenic Hemangiosarcoma, marks a significant advancement in the fight against hemangiosarcoma, the most prevalent and deadly cancer in dogs. This presentation highlights FidoCure’s work to connect cutting-edge science with one of the most pressing unmet needs in animal health.
